AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00951574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium
Description: Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
Study NCT00951574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution (placebo)
Description: Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
Study NCT03064815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Description: A stool test to measure inflammation in the gut.
Study NCT02517476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
Study NCT00322400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
Study NCT00322400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days.
Study NCT01553318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
Study NCT01553318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
Study NCT02350712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
Study NCT01904578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true accupressure
Description: Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
Study NCT01904578 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupressure
Description: Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
Study NCT00319111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)
Study NCT04476082 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study only
Description: No intervention - observational study only
Study NCT02350712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
Study NCT02265848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
Study NCT02265848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
Study NCT02350712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
Study NCT02350712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
Study NCT01917409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional laryngoscopy
Description: the device is to assist nasotracheal intubation
Study NCT04475016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/m² IV over 30 minutes on Day 1
Study NCT04475016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1200 mg/m² IV over 2 hours on Days 1-3
Study NCT04475016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² IV over 2 hours on Days 1-3
Study NCT04475016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400 mg IV on Day 1
Study NCT04475016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab
Description: 240 mg IV on Day 1
Study NCT03379909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin orally at doses up to 1500 mg twice daily for 3 months.
Study NCT02153801 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .
Description: For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter.
Study NCT02153801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .
Description: For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter.
Study NCT00402701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking School Bus Program
Description: Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
Study NCT01834105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pills
Study NCT02776332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Expression of Breastmilk
Description: Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
Study NCT04957017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training
Study NCT01073904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028)
Description: Single dose of 1.5 mg coated tablet
Study NCT01073904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postinor 2
Description: Single dose of 1.5 mg tablet
Study NCT03274635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
Study NCT03274635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
Study NCT01249976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood culture
Description: blood culture
Study NCT00701506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patterned Electrical Neuromuscular Stimulation
Description: * 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings
Study NCT00701506 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PENS
Description: * 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings.
Study NCT02612363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine for sedation
Description: Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose
Study NCT02612363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine for sedation
Description: Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose
Study NCT02592486 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®
Description: Injections of pneumococcal vaccine and influenza vaccine simultaneously.
Study NCT02592486 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sequential administration of Pneumovax NP® and Fluvic HA syringe®
Description: Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
Study NCT01266499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin (Polymyxin E) 100mg x 4/d
Description: Colistin (Polymyxin E) 100mg x 4/d
Study NCT01266499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: both medications
Description: PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
Study NCT01917409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-stylet
Description: the device is to guide the nasotracheal tube into trachea
Study NCT01268176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU once per month for 3 months
Study NCT02267096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
Study NCT02267096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Treatment
Description: A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
Study NCT02267096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Treatment
Description: A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
Study NCT02337179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision
Description: Male Circumcision Under Local Anesthesia using the Forceps Guided Method
Study NCT04072718 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
Study NCT01816698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurine granule
Description: 1 package(1.6g taurine granule) once a day after meals, 12 weeks
Study NCT01816698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 package once a day after meals, 12 weeks
Study NCT04409366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Crown Lengthening (CCL)
Description: Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days
Study NCT04409366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-stage Crown Lengthening (SCL)
Description: In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
Study NCT01165996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given subcutaneously
Study NCT01165996 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01165996 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study NCT04701697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion
Study NCT04701697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HumanAlbumin
Description: Participants will receive HumanAlbumin of intravenous infusion
Study NCT03465371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSC OnDemand Training Intervention
Description: Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials
Study NCT03465371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InPerson Intervention
Description: Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role
Study NCT03465371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual InPerson Intervention
Description: Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role
Study NCT02720952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: dry granule formulation of hydrocortisone
Study NCT04261257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac scanner
Description: As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out.